The efficacy and safety of ceftriaxone in the treatment of bacteremic typhoid fever was studied in 14 patients. Ceftriaxone at a dosage of 50 to 60 mg/kg per day was administered intravenously in two divided doses in 13 patients and as a single dose in 1 patient. When the two patients with medical complications causing persistent fever and the patient who was febrile during therapy were excluded from the calculations, the mean period of defervescence was 4 days. Five to eight days of ceftriaxone therapy was adequate for the patients who were cured. The 14 patients treated with ceftriaxone included 13 patients who were considered cured, although 1 was a convalescent carrier, and one patient who was a treatment failure. There were no relapses in the 11 patients who were monitored for 1 to 8 moniths. Both peak and trough concentrations of ceftriaxone were well above the ceftriaxone MICs for the Salmonella typhi strains isolated from the patients. We have demonstrated that ceftriaxone can be used successfully in the treatment of typhoid fever in some patients. The advantages of its use include rapid clinical response, short course of treatment, and lack of serious adverse drug reactions.
The antimicrobial therapy of typhoid fever has not changed over the years despite the availability of many new antimicrobial agents. Chloramphenicol is still considered the drug of choice (5) . Ampicillin and cotrimoxazole are usually the alternative choices. The use of chloramphenicol in the treatment of typhoid fever has three disadvantages: the risk of developing aplastic anaemia, which is a rare but potentially fatal complication (9) ; a relapse rate of approximately 10% (6, 7) ; and the prolonged course (2 weeks) of treatment. In addition, in our experience, the duration of therapy before defervescence was 6 to 11 days in more than two-thirds of our patients. Therefore, an antimicrobial agent which is efficacious but without these disadvantages would be an advancement in the management of typhoid fever.
In vitro studies have shown that ceftriaxone is highly active against Salmonella typhi (3) . A report on the successful treatment of typhoid fever with ceftriaxone at different dosages has also been published in abstract form (0. MaciasHernandez, N. P. Quintero, G. Campa-Uribe, J. A. PerezRuvalcaba, 0. Hernandez-Bugarin, J. J. RodriguezChagollan, J. S. Andrade-Perez, and E. Rodriguez-Noriega, Program Abstr. 23rd Intersci. Conf. Antimicrob. Agents
Chemother., abstr. no. 1005, 1983) . The objective of our project was to evaluate the efficacy and safety of ceftriaxone in the treatment of bacteremic typhoid fever in an open, nonrandomized pilot study.
MATERIALS AND METHODS
Patients. Patients admitted to Middleton Hospital with typhoid fever confirmed by the isolation of S. typhi from blood cultures were considered eligible for the trial. Patients were included if they had none of the following exclusion criteria: known penicillin or cephalosporin allergy; pregnancy, complications of typhoid fever, e.g., shock, meningitis, gastrointestinal hemorrhage, or peritonitis; ampicillin (>2 g/day) or chloramphenicol therapy for more than 24 h prior to entry into the study. Informed consent was obtained * Corresponding author. from all the adult patients and from the guardians of patients 3, 13, and 14.
Ceftriaxone was administered intravenously over 30 min at a dosage of 50 to 60 mg/kg per day given in two divided doses for 7 days. High fever was managed by tepid sponging, and antipyretic was prescribed only when temperature was >40°C despite sponging. One of the investigator physicians examined the patients daily, and temperature and pulse rate were monitored every 4 h. Patients were withdrawn from the study if the S. typhi isolated from blood culture was found to be resistant to ceftriaxone by the disk susceptibility test (considered susceptible if the zone of inhibition was <16 mm with a 30-,ug disk) or if there was development of a severe drug reaction or complications of the disease which the physician felt were best treated with chloramphenicol. If the patient responded to therapy, ceftriaxone was continued for 24 to 72 h following defervescence. Ceftriaxone was discontinued at the end of 7 days if the patient continued to be febrile. If the patient's condition was stable, he or she was observed without any antimicrobial treatment for 48 to 72 h. During this period, blood cultures were done daily, and other causes of fever, e.g., malaria and amoebiasis, were investigated. At the end of 48 to 72 h, the patient was treated with intravenous chloramphenicol if the temperature remained elevated and no other causes of fever could be found.
Full blood count and tests for creatinine, electrolytes, and liver function were done before administration of the drug, during days 1 to 3 of treatment and on the last day of treatment. Peak (30 min following completion of intravenous infusion) and trough (just before administration of dose) concentrations of ceftriaxone were determined on day 2 or 3 and at the end of treatment. Blood cultures were done on day 3 if the temperature was >37.5°C. The patient was considered febrile if the oral temperature was above 37.5°C.
Evaluation of response to therapy. In this study the outcome of ceftriaxone therapy was divided into five categories, i.e., cure, convalescent carrier, failure, relapse, and death. The patient was considered cured if there was a resolution of all clinical signs and symptoms with negative stool and urine cultures for S. typhi at the end of the treatment and if the patient remained well during the follow-up period. A failure was diagnosed when there was a lack of defervescence and no other cause of pyrexia (including drug fever) could be found. The diagnosis of failure was confirmed if blood cultures for S. typhi were positive or if the patient responded to chloramphenicol therapy. A convalescent carrier was a patient who responded clinically and remained well but continued to excrete S. typhi in the stool at the completion of treatment. A diagnosis of relapse was made if the patient responded to treatment clinically and then had a recurrence of fever with blood culttires positive for S. typhi within 2 months following completion of therapy arid with no evidence of exposure to suggest a new infection. Follow-up. Patients were instructed to return to the hospital if fever recurred. They were usually reviewed, and three stool specimens were cultured for S. typhi within 3 months of discharge from the hospital, but the period was extended for patients who were unable to return within that time.
Microbiology. S. typhi isolated from blood cultures was bacteriophage typed, and sensitivity to ceftriaxone was determined by the agar diffusion method of Bauer et al. (1) . The MICs of ceftriaxone against the S. typhi strains were determined by the agar dilution method.
Drug assay. Ceftriaxone concentration in serum was determined by ion pair reversed-phase high-pressure liquid chromatography by a method slightly modified from that of Trautmann and Haefelfinger (10) .
RESULTS
A total of 14 patients (9 males and 5 females) with bacteremic typhoid fever were treated with ceftriaxone.
They ranged in age from 10 to 61 years ( Table 1 ). The period of illness prior to institution of ceftriaxone therapy varied from 6 to 28 days.
Temperature respohse during ceftriaxone therapy. Two different patterns of oral temperature response to ceftriaxone therapy were seen in patients (Table 1) .
(i) Responders. Ten patients responded with defervescence within 6 days or less of therapy. Of these 10 patients, 3 became afebrile within 2 or 3 days. A feeling of well-being and improvement of appetite followed the same course.
(ii) Nonresponders. There were two types of patients who were considered nonresponders. One type of nonresponder included patients whose persistent fever was due either to complications of the drug therapy or to other medical problems. Three patients were in this group. Patient no. 2 was found to have amoebic gastroenteritis in addition to typhoid fever, and on treatment with metronidazole, his low-grade fever subsided. Patient no. 10 developed severe thrombophlebitis on days 4 and 5 of therapy, and ceftriaxone was discontinued on day 5 because of chills and rigors and a fever of 40.9°C. His fever resolved following discontinuation of ceftriaxone, and he received no further antibiotic therapy. Patient no. 7 had a temperature of 38.3°C on the last day of therapy, and the fever resolved within 24 h of discontinua- tion of treatment. Her fever was decreasing, but very gradually, during the treatment period. She was probably a slow responder; The other type of nonresponder was a patient who was considered a treatment failure. During days 1 and 2 of treatment, he seemed to have responded by a fall of temperature from 39.8 to 39.5°C. However, the temperature remained around 39°C for the rest of the treatment period and after the discontinuation of ceftriaxone. Blood cultures done during ceftriaxone treatment and on 2 consecutive days while the patient was not on any antibiotics were sterile. The temperature decreased rapidly after 48 h of intravenous chloramphenicol treatment. He completed the course of chloramphenicol therapy and remained well afterward.
Blood cultures done during therapy. Blood cultures were done on all patients at day 2 or 3 of ceftriaxone therapy, and the cultures were all sterile.
Outcome of therapy. Of the 14 patients with bacteremic typhoid fever, 13 were cured, with 1 patient being a convalescent carrier. The follow-up periods for 11 patients ranged from 1 to 8 months, and no relapses were seen. Two patients who were cured at the time of discharge from the hospital were lost to follow-up. One patient was considered a ceftriaxone treatment failure. There were no deaths in this study (Table 1) .
Ceftriaxone concentrations in serum and MIC of ceftriaxone against S. typhi. Al the S. typhi strains isolated from the 14 patients had an MIC of ceftriaxone in the range of 0.016 to 0.063 Fjg/ml (Table 2) . Excluding the patient who was given the drug once a day, the mean peak and trough concentrations in serum were 199.8 (range, 134 to 265) and 46.2 (range, 28 to 84) ptg/ml, respectively, at the beginning of therapy.
Towards the end of therapy, the mean peak and trough concentrations in serum were 219.9 (range, 110 to 305) and 58.1 (range, 30 to 86) p,g/ml, respectively (Table 1) .
Adverse drug effects. The most common adverse reaction associated with the use of ceftriaxone was phlebitis in three patients. One of these patients also developed diarrhea during therapy. In this patient, ceftriaxone therapy was discontinued due to the high fever associated with chills and rigors which, we suspected, may have been caused by both phlebitis and drug fever. Laboratory test abnormalities were noted mainly in the total leukocyte count and the liver function tests. One patient had a pretreatment leukocyte count of 4,800/Rl3, and this count decreased to 2,900/pd13 at the end of treatment. All the patients had mild elevations of Table 1. liver enzymes before treatment, but in three patients, the alanine aminotransferase levels in serum at the end of treatment were higher than the midtreatment levels.
DISCUSSION
In this study of 14 bacteremic typhoid fever patients who were treated with ceftriaxone, there was only one treatment failure. Therefore, we have shown that ceftriaxone can be used successfully in the treatment of typhoid fever. In addition, there were two advantages in using ceftriaxone. One advantage was the rapid resolution of fever. When the two patients with medical complications causing persistent fever and the patient (no. 7) who was febrile during therapy were excluded from the calculations, the mean period of defervescence while on treatment was 4 days. The other advantage was the short course of treatment. In the study, approximately 7 days of ceftriaxone therapy was adequate for the patients who were cured. This is a much shorter course than the 14 days generally required for chloramphenicol treatment. These advantages are again evident when our study is compared with that of Uwaydah et al. (11) . In their study, cefamandole given as a continuous intravenous infusion for at least 10 to 15 days cured five patients with typhoid fever. The drug failed to control the infection in three of four patients who were treated with intermittent intravenous therapy.
The dosage of ceftriaxone used in this study was 50 to 60 mg/kg per day. It was felt that this dosage would achieve a sufficiently high concentration in serum to treat a serious sepsis. For all the patients, the trough concentration of ceftriaxone in serum was at least 1,000 times that of the ceftriaxone MIC for the S. typhi strains that were isolated from the patients. The peak concentration in serum was three times that of the trough concentration. Therefore, throughout the period of treatment, the drug concentration in the blood was well above the ceftriaxone MIC for the organisms. Whether this fact means that a lower dose of ceftriaxone than the dosage prescribed in the study could be used would require further study. But it should be noted that in this study, the lowest peak concentration of ceftriaxone in serum towards the end of therapy was found in the patient who was a treatment failure. It is possible that the low concentration in serum contributed to the failure, as there was no other obvious cause for it.
Ceftriaxone was generally well tolerated in our study, as was reported in the studies in which it was used in the treatment of other bacterial sepsis (2, 4). Although only one patient in our study demonstrated a fall in the total leukocyte count to 2,900/,u13, it would be important to monitor closely the hematological parameters, as abnormalities such as leukopenia and thrombocytopenia have been observed in other studies (2, 4) . Abnormal liver function tests are not uncommon in patients with typhoid fever (8) . However, the significance of the further increase in levels of alanine aminotransferase in serum during treatment as observed in our study is not known. The increase in enzyme levels could be due to the evolution of the disease or to adverse drug reaction. Therefore, it would be advisable to monitor the liver function test during ceftriaxone therapy, especially if high doses of the drug are administered.
In this study we have shown that some patients with bacteremic typhoid fever were successfully treated with ceftriaxone. However, it should be pointed out that the status of "cure" in the two patients who were lost to follow-up is less certain than in the others. We also realize that although our results were encouraging, the number of patients in our study was small and all the patients were noncomplicated cases of typhoid fever. Therefore, whether ceftriaxone is superior, equal, or inferior to chloramphenicol in cure, relapse, or carrier rates will have to be determined by future randomized comparative studies.
